Clinical Trial Agreement Template and How to Draft One (2026)

What is a clinical trial agreement, and when do you need one? A clinical trial agreement (CTA) is the contract that governs a clinical trial between the parties who run it: typically the sponsor (often a pharmaceutical or medical-device company or a contract research organisation acting for it), the trial site or institution, and sometimes the principal investigator. It sets out who does what, who pays, who owns the data and results, how trial-subject injuries are handled, and how the parties follow the law and ethics rules that govern research on human participants. You need a CTA whenever a clinical trial is run at a site on behalf of a sponsor. It is distinct from the trial protocol (the scientific plan) and from the informed-consent documents that participants sign. The CTA is the commercial and legal wrapper: it makes the protocol binding, allocates risk and money, and ties the whole trial to the regulatory regime. In India, clinical trials are governed by the New Drugs and Clinical Trials Rules, 2019, administered by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs Controller General of India (DCGI). The rules require approval of the trial, a registered ethics committee overseeing it, and compensation for trial-related injury or death, with medical management of injured participants. <!-- [VERIFY: whether a signed CTA is itself a named rule requirement vs standard practice under NDCT Rules 2019 --> Indian Council of Medical Research (ICMR) ethical guidelines also apply. <!-- [VERIFY: current ICMR guidelines edition] --> This article is general guidance, not legal advice. The law here varies by jurisdiction and changes over time, so have a qualified lawyer review any agreement before you rely on it. ## Clinical trial agreement template Copy the block below and fill the bracketed fields. This is a simplified starting point; a real CTA is longer and must match the approved protocol and local rules. ```

CLINICAL TRIAL AGREEMENT This Clinical Trial Agreement ("Agreement") is made on [DATE] BETWEEN: [SPONSOR NAME], [address] ("Sponsor") [and [CRO NAME] acting for the Sponsor] AND [INSTITUTION / SITE NAME], [address] ("Institution") [and [PRINCIPAL INVESTIGATOR NAME] ("Investigator")] 1. THE STUDY The Institution will conduct the clinical trial described in Protocol [number/version] (the "Study") strictly in line with the Protocol, the approvals, Good Clinical Practice, and applicable law. 2. REGULATORY AND ETHICS APPROVALS The Study will start only after the required regulatory approval and the approval of the registered Ethics Committee, and will continue only while those approvals are valid. 3. INFORMED CONSENT The Investigator will obtain and document informed consent from each participant as the Protocol and applicable rules require, before any Study procedure. 4. OBLIGATIONS OF THE PARTIES The Sponsor will provide [the investigational product, the Protocol, funding, and safety information]. The Institution and Investigator will conduct the Study, keep records, and report as required. 5. STUDY BUDGET AND PAYMENTS The Sponsor will pay the amounts in the Budget in Schedule 1, on the milestones stated. [Payments are per participant / per visit / on milestones.] No payment is contingent on a particular result. 6. PARTICIPANT INJURY AND COMPENSATION The Sponsor is responsible for the costs of medical management of a participant for a Study-related injury, and for compensation for Study-related injury or death, as required by applicable law and the Ethics Committee's determination. 7. INSURANCE AND INDEMNITY The Sponsor will maintain clinical-trial insurance and will indemnify the Institution and Investigator against claims arising from the proper conduct of the Study, except to the extent caused by their negligence or failure to follow the Protocol or law. 8. DATA, RECORDS AND SOURCE DOCUMENTS Study data and records will be kept as the Protocol and rules require, retained for [the period required by law], and made available for monitoring, audit and inspection. 9. OWNERSHIP OF RESULTS AND INTELLECTUAL PROPERTY The Study data and results, and any intellectual property arising from the Study, belong to [the Sponsor], subject to the Institution's and Investigator's rights to [use data for internal research / publish per clause 11]. 10. CONFIDENTIALITY Each party will keep the other's confidential information private and use it only for the Study. 11. PUBLICATION The Investigator may publish Study results after [N] days notice to the Sponsor, who may ask for a short delay to protect patentable subject matter or remove its confidential information, but may not suppress or alter the results. 12. DATA PROTECTION Each party will handle participant personal and health data as applicable data-protection law requires, including de-identification where appropriate. 13. TERM AND TERMINATION This Agreement runs until the Study ends or either party terminates on the grounds stated. On termination, participant safety and the required reporting continue. 14. GOVERNING LAW AND DISPUTES This Agreement is governed by the laws of [jurisdiction]. Disputes are subject to [courts / arbitration]. Signed for the Sponsor: __________ Signed for the Institution: __________ Name / title / date Name / title / date Investigator: __________

- **Approvals (clause 2).** Tie the start and continuation of the trial to valid regulatory and registered ethics-committee approval. In India this is approval under the New Drugs and Clinical Trials Rules, 2019 and a registered ethics committee.
- **Budget and payment (clause 5).** State the budget and milestones, and make clear no payment depends on reaching a particular result, which protects the integrity of the trial.
- **Injury and compensation (clause 6).** This is the clause regulators care about most. The sponsor is responsible for medical management of study-related injury and for compensation for injury or death, as the law and the ethics committee require.
- **Insurance and indemnity (clause 7).** The sponsor carries clinical-trial insurance and indemnifies the site and investigator for the proper conduct of the trial, with carve-outs for their own negligence or protocol breach.
- **Ownership and publication (clauses 9 and 11).** Sponsors usually own the data and results; investigators keep a right to publish after a short review window. The sponsor may delay to protect patents or remove confidential information, but must not suppress or alter results.
- **Data protection (clause 12).** Participant health data is sensitive personal data. Handle it under the applicable data-protection law and de-identify where possible. ## Common mistakes to avoid - Starting any study procedure before regulatory and ethics-committee approval, or before informed consent.
- A compensation and medical-management clause that does not match what the law and the ethics committee require.
- Making any payment contingent on a particular result, which compromises the trial.
- A publication clause that lets the sponsor suppress or edit unfavourable results, rather than only delay to protect patents.
- No clear data-retention period or audit and inspection rights.
- Ignoring participant data-protection obligations for sensitive health data. ## A note on jurisdiction Clinical trials are among the most heavily regulated contracts, and the rules are national. In India the governing framework is the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, administered by CDSCO and the DCGI, with registered ethics committees, mandatory compensation for trial-related injury or death, and ICMR ethical guidelines. The United States (FDA regulations and the Common Rule), the United Kingdom, Ireland and the EU (the EU Clinical Trials Regulation and local law), Singapore and Australia each have their own approval, consent, compensation and data rules. International sponsors also apply the ICH Good Clinical Practice standard. Treat compensation, insurance, data protection and ownership as points to confirm against the law of the country where the trial runs rather than assume one answer fits all. ## Where a contract workspace helps A clinical trial agreement has to stay consistent across many versions and counterparties, with each draft checked for weak indemnity, compensation or publication terms and the approval dates and reporting duties remembered long after signing. Drafting, reviewing, tracking and governing a clinical trial agreement can live in one AI workspace tuned to your approved protocol and house terms, with the clauses linked so per-clause risk shows and the key dates and obligations stay in view. [Adira](https://adiralaw.com) is one tool built around that single-workspace idea for study contracts like a CTA. This template alone is enough to structure a sound clinical trial agreement.